Nan Fung Group Holdings Ltd - Q2 2024 holdings

$93.7 Million is the total value of Nan Fung Group Holdings Ltd's 44 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 20.0% .

 Value Shares↓ Weighting
ILMN  ILLUMINA INC$12,441,678
-24.0%
119,1960.0%13.27%
-12.5%
HRMY  HARMONY BIOSCIENCES HLDGS IN$11,122,623
-10.2%
368,6650.0%11.87%
+3.5%
MRUS BuyMERUS N V$7,102,648
+76.2%
120,038
+34.1%
7.58%
+102.9%
GERN BuyGERON CORP$5,823,852
+33.2%
1,373,550
+3.7%
6.21%
+53.4%
 OCULIS HOLDING AGordinary shares$5,214,717
-0.8%
436,3780.0%5.56%
+14.2%
INCY  INCYTE CORP$4,487,214
+6.4%
74,0220.0%4.79%
+22.5%
 EXSCIENTIA PLCads$4,385,449
-10.8%
859,8920.0%4.68%
+2.7%
XENE  XENON PHARMACEUTICALS INC$4,159,453
-9.4%
106,6800.0%4.44%
+4.3%
LBPH BuyLONGBOARD PHARMACEUTICALS IN$3,907,727
+53.0%
144,570
+22.3%
4.17%
+76.1%
MIRM BuyMIRUM PHARMACEUTICALS INC$3,627,559
+50.3%
106,100
+10.4%
3.87%
+73.0%
FLDM  STANDARD BIOTOOLS INC$3,333,227
-34.7%
1,883,1790.0%3.56%
-24.8%
BGNE  BEIGENE LTDsponsored adr$3,284,549
-8.8%
23,0220.0%3.50%
+5.0%
KALV  KALVISTA PHARMACEUTICALS INC$2,583,083
-0.7%
219,2770.0%2.76%
+14.4%
RYTM  RHYTHM PHARMACEUTICALS INC$2,016,867
-5.2%
49,1200.0%2.15%
+9.1%
BuyTOURMALINE BIO INC$1,887,848
+292.8%
146,800
+599.5%
2.01%
+352.6%
 RANI THERAPEUTICS HLDGS INC$1,875,619
+22.2%
493,5840.0%2.00%
+40.7%
ASND  ASCENDIS PHARMA A/Ssponsored adr$1,854,768
-9.8%
13,6000.0%1.98%
+3.9%
REPL  REPLIMUNE GROUP INC$1,844,451
+10.2%
204,9390.0%1.97%
+26.9%
ACAD  ACADIA PHARMACEUTICALS INC$1,673,490
-12.1%
102,9840.0%1.78%
+1.2%
MDGL  MADRIGAL PHARMACEUTICALS INC$1,591,869
+4.9%
5,6820.0%1.70%
+20.8%
EXEL  EXELIXIS INC$1,442,574
-5.3%
64,2000.0%1.54%
+9.0%
ZLAB NewZAI LAB LTDadr$953,15055,000
+100.0%
1.02%
BMRN  BIOMARIN PHARMACEUTICAL INC$890,399
-5.7%
10,8150.0%0.95%
+8.6%
BOLT  BOLT BIOTHERAPEUTICS INC$875,214
-46.4%
1,166,9520.0%0.93%
-38.3%
 ENTRADA THERAPEUTICS INC$699,419
+0.6%
49,0820.0%0.75%
+15.8%
ATHA  ATHIRA PHARMA INC$477,000
-3.3%
180,0000.0%0.51%
+11.4%
PACB  PACIFIC BIOSCIENCES CALIF IN$376,049
-63.5%
274,4880.0%0.40%
-58.0%
CABA  CABALETTA BIO INC$352,682
-56.2%
47,1500.0%0.38%
-49.5%
BCYC NewBICYCLE THERAPEUTICS PLCsponsored ads$350,15217,300
+100.0%
0.37%
 ROIVANT SCIENCES LTD$343,208
+0.3%
32,4700.0%0.37%
+15.5%
KYMR  KYMERA THERAPEUTICS INC$324,619
-25.7%
10,8750.0%0.35%
-14.6%
NewGRAIL INC$305,34019,866
+100.0%
0.33%
RVMD  REVOLUTION MEDICINES INC$283,313
+20.4%
7,3000.0%0.30%
+38.5%
SWTX  SPRINGWORKS THERAPEUTICS INC$280,642
-23.5%
7,4500.0%0.30%
-12.1%
ALXO  ALX ONCOLOGY HLDGS INC$252,959
-45.9%
41,9500.0%0.27%
-37.6%
IMCR  IMMUNOCORE HLDGS PLCads$228,758
-47.9%
6,7500.0%0.24%
-40.0%
 AFFIMED N V$202,996
+2.8%
37,2470.0%0.22%
+18.6%
IMTX  IMMATICS N.V$182,434
+10.6%
15,7000.0%0.20%
+27.5%
BMEA  BIOMEA FUSION INC$180,000
-69.9%
40,0000.0%0.19%
-65.3%
ABCL  ABCELLERA BIOLOGICS INC$150,874
-34.7%
50,9710.0%0.16%
-24.8%
NewDBV TECHNOLOGIES S Asponsored adr$148,565185,475
+100.0%
0.16%
AVTE  AEROVATE THERAPEUTICS INC$79,574
-94.4%
47,9360.0%0.08%
-93.5%
KOD  KODIAK SCIENCES INC$75,017
-55.3%
31,9220.0%0.08%
-48.7%
FGEN  FIBROGEN INC$55,417
-62.0%
62,1060.0%0.06%
-56.3%
GRTX ExitGALERA THERAPEUTICS INC$0-613,223
-100.0%
-0.08%
BCRX ExitBIOCRYST PHARMACEUTICALS INC$0-36,847
-100.0%
-0.17%
DBVT ExitDBV TECHNOLOGIES S Asponsored adr$0-370,950
-100.0%
-0.26%
ExitNEUMORA THERAPEUTICS INC.$0-63,315
-100.0%
-0.81%
ALPN ExitALPINE IMMUNE SCIENCES INC$0-263,940
-100.0%
-9.69%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2024-08-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
HARMONY BIOSCIENCES HLDGS IN13Q2 202421.3%
XENON PHARMACEUTICALS INC13Q2 20244.4%
BOLT BIOTHERAPEUTICS INC13Q2 20245.6%
KALVISTA PHARMACEUTICALS INC13Q2 20242.8%
EXELIXIS INC13Q2 20241.5%
ALX ONCOLOGY HLDGS INC13Q2 20241.0%
ILLUMINA INC12Q2 202421.5%
RANI THERAPEUTICS HLDGS INC12Q2 20243.5%
GALERA THERAPEUTICS INC12Q1 20241.9%
DBV TECHNOLOGIES S A12Q1 20240.6%

View Nan Fung Group Holdings Ltd's complete holdings history.

Latest significant ownerships (13-D/G)
Nan Fung Group Holdings Ltd Q2 2024 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Eargo, Inc.December 16, 20222,958,0990.7%
Stealth BioTherapeutics CorpJanuary 09, 202020,240,8174.8%
New Frontier Health CorpJanuary 02, 20209,650,0007.3%

View Nan Fung Group Holdings Ltd's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-11-13
N-PX2024-08-30
13F-HR2024-08-13
13F-HR2024-05-14
13F-HR2024-02-13
13F-HR2023-11-13
13F-HR2023-08-11
13F-HR2023-05-12
13F-HR2023-02-13
SC 13D/A2022-12-16

View Nan Fung Group Holdings Ltd's complete filings history.

Compare quarters

Export Nan Fung Group Holdings Ltd's holdings